67 results about "CD36" patented technology

The present invention relates to the technical field of genetic engineering. Particularly provided are an identification marker for early chronic obstructive pulmonary disease and the use thereof in a diagnostic kit. The identification marker for the early chronic obstructive pulmonary disease is screened, which is miRNA1255a in serum-derived exosomes; in addition, biological function analysis after sequencing proves that among a plurality of target genes of miRNA1255a, the tissue inhibitor of metalloprotease (TIMP-2) and CD36, which are genes related to the protease / antiprotease balance, are involved in the Ca ion signaling pathway, and moreover, the expression of CD36 and TIMP-2 proteins proves that said two proteins are negatively correlated with miRNA1255a. Moreover, it is found in detection results that the expression of TIMP-2 and the expression of CD36 are all downregulated when the expression of miRNA1255a is upregulated. The biomarker for the early chronic obstructive pulmonary disease is provided, which can easily screen potential patients with early onset of chronic obstructive pulmonary disease.

The invention belongs to the technical field of biomedical materials, and discloses light-controlled liquefied hydrogel for inhibiting wound scar formation and a preparation method and application thereof.The light-controlled liquefied hydrogel is prepared from 6-18 parts of PVA hydrogel, 3-9 parts of borax boric acid buffer solution and 1-3 parts of PDA (at) CeO2-SAB nano-particle suspension.The hydrogel has the advantages that light-controlled liquefaction can be achieved, and the hydrogel can be applied to wound scar formation. The material has the characteristics of uniform particle size, accurate drug release, inhibition of CD36 expression, good biocompatibility, biodegradability and the like, can be used for infected wounds, and provides a novel, simple and effective material for wound inflammation inhibition and scar repair resistance treatment.

The present disclosure describes methods of specifically modulating the activity and / or number of regulatory T (Treg) cells within a tumor in a subject. Such methods may be used to reduce the number of regulatory T cells within a tumor in a subject, as well as to inhibit tumor growth in a subject with cancer without eliciting an autoimmune response. This method relies on the inhibition of CD36 or PPARbeta.

The present disclosure generally relates to binding agents capable of targeting tumor cells and / or immune cells and their use to treat cancer. The binding agents of the present disclosure comprise one or more antigen-binding domains of a single-domain antibody capable of binding to cluster of differentiation 36 (CD36), programmed cell death protein 1 (PD-1), and / or cluster of differentiation 47 (CD47). The binding agents of the present disclosure may be monospecific or multispecific and may be in monomeric or multimeric form.

The present invention relates to the technical field of biology, and particularly relates to a method for inhibiting an inflammatory response by using a fibroblast. In the present invention, a fibroblast, which is obtained by digesting normal foreskin tissue by means of clostridiopeptidase A to isolate a cell as a seed cell and culturing the seed cell in vitro by using a serum-free medium, shows positive expression of CD105, CD90, CD73, COL1A1, and FAP, with expression rates all exceeding 80%, and negative expression of CD36, CD39, CD45, and HLA class II molecules, with expression rates below 5%. The fibroblast can regulate an immune response by secreting TGFβ, inhibiting proliferation of PBMCs, thereby inhibiting the inflammatory response, and has been verified in an animal experiment to have the ability to repair knee osteoarthritis caused by meniscus injury. Therefore, the fibroblast can be used for preventing and treating inflammatory lesions such as osteoarthritis.

The invention discloses an antibody composition for detecting mother cell plasma cell-like dendritic cells. The antibody composition comprises a first group of antibodies, a second group of antibodies, a third group of antibodies and a fourth group of antibodies, the first group of antibodies comprises a CD36 antibody, a CD4 antibody, a CD14 antibody, a CD56 antibody, a CD5 antibody, a CD3 antibody, a CD8 antibody, a CD2 antibody, a CD7 antibody and a CD45 antibody; the second group of antibodies comprises an HLA-DR (Human Leukocyte Antigen-DR) antibody, a CD33 antibody, a CD34 antibody, a CD56 antibody, a CD117 antibody, a CD123 antibody, a CD19 antibody, a CD38 antibody and a CD45 antibody; the third group of antibodies comprises a CD303 antibody, a CD304 antibody, a CD41 antibody, a CD56 antibody, a CD13 antibody, a CD85j antibody, a CD64 antibody, a CD15 antibody and a CD45 antibody; and the fourth group of antibodies comprises TdT, MPO, CD56, cCD3, CD10, cCD22 and CD45 antibodies. The antibody composition can be used for accurately detecting tumor abnormal BPDCN cells.

The invention discloses application of rutin hydrate in preventing and treating repeated embryo planting failure, and belongs to the technical field of assisted reproduction. It is found for the first time that CD36 is a key membrane protein for lipid transport and uptake of EECs, rutin hydrate competitively inhibits combination of CD36 and natural ligands of CD36, abnormal lipid excessive uptake is remarkably blocked, lipid accumulation and lipid toxicity damage in cells are effectively relieved, and the effect of inhibiting EECs lipid transport and uptake is achieved. And finally, the endometrial receptivity defect related to RIF is reversed, and the embryo adhesion and implantation capability is remarkably improved. Therefore, rutin hydrate provides a brand new strategy for developing targeted therapy drugs for RIF, especially for lipid metabolism disorder type endometrial receptivity badness, and has remarkable clinical application and transformation prospects.

This invention discloses the application of reagents for detecting biomarker levels in the preparation of products for identifying obstructive sleep apnea. It relates to the field of biomarker technology and aims to overcome the shortcomings of existing technologies that rely on complex polysomnography (PSG) procedures, poor patient compliance, and a lack of effective molecular markers. The biomarkers used in this application consist of CD36 glycoprotein, 9-octadecenal, and protocatechuic acid 3-O-sulfate. This invention enables rapid and objective identification of obstructive sleep apnea by detecting the levels of the above biomarkers in plasma. The procedure is simple and well-accepted by patients. The combined use of multiple biomarkers can improve the accuracy and stability of the identification, making it suitable for screening or auxiliary diagnosis in medical institutions at different levels.

The invention relates to the technical field of medicines, in particular to application of an integrin beta3 inhibitor RGDfK in preparation of a medicine for treating metabolic dysfunction related fatty liver diseases. The RGDfK provided by the invention can inhibit palmitoylation and membrane localization of CD36 in liver tissues of mice with fatty liver diseases related to metabolic dysfunction induced by high fat diet feeding, so that lipid uptake of the liver is inhibited. Experimental results show that RGDfK can improve obesity and insulin resistance of mice with metabolic dysfunction-related fatty liver diseases, can improve fat accumulation, fibrosis and inflammatory infiltration of liver tissues of the mice with fatty liver diseases, and is expected to become a new medicine for treating the metabolic dysfunction-related fatty liver diseases.

The present application provides siRNA and its application for specifically inhibiting CD36 gene expression. In particular, the present application provides siRNA, shRNA, recombinant vector, recombinant lentivirus, siRNA, host cell for specifically inhibiting CD36 gene expression, and its application in preparing a medicament for inhibiting CD36 gene expression / treating CD36 related diseases.

The invention discloses application of targeting CD36 in treatment of rheumatoid arthritis, and relates to the technical field of biological materials, and the technical key points are as follows: the CD36 is an effective target spot for treating the rheumatoid arthritis, the content of the CD36 in the body of an RA patient is reduced, and RA-FLS proliferation and release of inflammatory factors can be inhibited; a new molecular mechanism that CD36 participates in RA-FLS activation by regulating fatty acid metabolism is found, CD36 is a new target for relieving RA joint inflammation and injury, and a new treatment direction is provided for clinical treatment of RA.

The application discloses a kind of magnetic nanoparticles for atherosclerosis diagnosis and treatment.It is core-shell structure, the inner core is Fe₃O₄ magnetic nano material, shell is the drug-loading layer of biodegradable polymer material, the drug-loading layer is encapsulated with analog movement polypeptide K271la, and the surface of nano particle is covalently coupled with CD36 targeting antibody.Its preparation method mainly includes: by complex emulsification-solvent volatilization method, Fe₃O₄ nanoparticle and K271la polypeptide are co-encapsulated in one step, form nanoparticle, and then CD36 antibody is modified on the surface of particle by chemical coupling.The nanoparticle of the application has the ability of active targeting (CD36 antibody) and passive targeting (magnetic response), can be efficiently enriched in plaque, and deliver therapeutic polypeptide to macrophages, activate lipophagy to remove lipid;It can be used as magnetic resonance imaging contrast agent, realizes diagnosis and treatment integration, and provides a new strategy for solving the problem of low efficiency of atherosclerosis targeted therapy and lack of effective monitoring means.

The invention provides a biomarker combination for evaluating the progress of abdominal aortic aneurysm based on an adventitia and application of the biomarker combination, and the biomarker combination comprises at least two biomarkers selected from the following three independent groups, the at least two markers are from the same group or different groups: a myofibroblast transformation marker group: alpha-smooth muscle actin, monocyte chemotactic protein 1 and a tissue metalloproteinase inhibitor 1; the lipid metabolism related biomarker group comprises a lipid metabolism related protein CD36, carnitine palmitoyl transferase 1 and a fatty acid binding protein 4; and an inflammatory factor related biomarker group: IL-6, MCP-1 and TIMP1. According to the biological marker combination for evaluating the progress of the abdominal aortic aneurysm based on the adventitia, multi-channel biological markers are systematically integrated, an innovative tool is provided for accurate diagnosis, drug screening and curative effect monitoring of AAA, and meanwhile, an important foundation is laid for developing a collaborative treatment strategy based on adventitia fibroblast regulation.

The present invention discloses a diagnostic kit for autism spectrum disorder based on pan-apoptosis-related genes, which belongs to the field of biomedicine. The diagnostic kit for autism spectrum disorder based on the pan-apoptosis-related genes of the present invention includes a detection kit. <h2 style=";text-align:left;direction:ltr">CD36 <h2 style=";text-align:left;direction:ltr"> LMNB1, DNAJA1, MSH2, JAK2, PDCD4, DEK This study identified and screened key pan-apoptosis genes that were differentially expressed between children with autism spectrum disorder and healthy children. Using primer sequences for these key pan-apoptosis genes and internal reference genes, a diagnostic kit was constructed to calculate autism risk based on the expression levels of these key genes. External sample validation of the kit and its diagnostic efficacy was conducted, demonstrating positive results.

The present invention addresses the problem of providing: a genetically modified cultured cell or a genetically modified animal each allowing a human sapovirus to proliferate regardless of host characteristics as barriers to proliferation in mammalian cells; and an application of the cell or animal to a screening method. The present inventors have solved the problem by finding that a genetically modified cultured mammalian cell having a human CD36-encoding gene incorporated therein and a mammal having such a cell as a self-cell show acquired susceptibility to human sapovirus infection, and providing, for example, a screening method for a drug relevant to a human sapovirus on the basis of the finding.

The invention belongs to the technical field of stem cell biological medicine, and particularly relates to application of uterine blood mesenchymal stem cell outer vesicles. According to the application, external vesicles (MenSC-EVs) derived from MenSC are used as active ingredients, the MenSC-EVs effectively relieve the hepatic fibrosis condition of a mouse, the key effect of a Thbs1 / Cd36 signal on mediating intercellular communication in a fibrosis hepatic microenvironment is disclosed, and the therapeutic effect of the MenSC-EV on hepatic fibrosis and a potential molecular mechanism of the MenSC-EV are explored and confirmed.

The invention relates to the technical field of traditional Chinese medicine preparations, and discloses a salvia miltiorrhiza salvianolic acid and notoginsenoside composition, and the mass ratio of notoginsenoside to salvianolic acid in the composition is 1: 5 or 5: 3 or 3: 5. The invention further discloses application of the composition in preparation of drugs for preventing and treating vasculopathy related to metabolic syndromes of metabolic organs. The composition disclosed by the invention can be used for remarkably relieving liver lipid deposition induced by high-fat diet and reducing abnormal accumulation of white and beige fat; wherein the optimal compatibility ratio is 1: 5, and the mechanism of playing the role is related to down-regulation of the expression of liver lipid transport key protein CD36; the invention provides a new intervention strategy and compatibility basis for preventing and treating vasculopathy related to metabolic syndrome, and provides a precise intervention thought of'combining diseases and syndromes' for the research of early prevention of atherosclerosis.

The invention provides a gene marker combination and application thereof in a risk prediction model of premature eclampsia. The gene marker combination comprises a combination selected from GTF2H1, CD48, PBX1, PLA2G2A, ACVR1B, HMGB1, ERBB2, XRCC5, TGFBR2, NFKB1, EGF, TLR6, EZH2, IKZF1, EGFR and CD36, a combination of HIPK1, MTHFR, IL6R, RAB27A, UBE2I, CREBBP, SOX8, HNF4A, ICOS, LIF, TMPRSS6, DNMT3A, WWTR1, RASSF1, FOXP1, TLR2 and MAPK14, AGRN, ATP2B1, ELAC2, HDAC5, GABARAP, FXR2, NFE2L2,

The invention discloses colloidal gold chromatography test paper and a kit for detecting platelet CD36 antigen, the colloidal gold chromatography test paper comprises a bottom plate, a sample pad, a gold-labeled combination pad, a nitrocellulose membrane and a water absorption pad, the gold-labeled combination pad is coated with a colloidal gold labeled mouse anti-human CD36 IgG2a monoclonal antibody and a colloidal gold labeled quality control rabbit IgG polyclonal antibody; the nitrocellulose membrane is provided with a detection line coated with a human platelet CD36 antigen capture antibody and a quality control line coated with quality control goat anti-rabbit polyclonal antibody molecules. When the kit is used for detecting the CD36 antigen, a detected sample is fully split by the platelet lysis buffer and then is added into the sample adding hole of the kit, and a detection result can be observed after waiting for 10-15 minutes. By adopting the detection mode provided by the invention, the CD36 antigen on the human platelets can be quickly, simply, conveniently, sensitively and specifically detected.

Disclosed herein, are compositions comprising bacterial strains from Clostridia or Bacilli, and methods of treating obesity, metabolic syndrome, inflammatory bowel disease, as well as reducing weight gain, inhibiting lipid absorption in the small intestine and downregulating CD36 in the liver or small intestine by administering the compositions to a subject.

The present disclosure generally relates to binding agents that are capable of targeting tumor cells and / or immune cells and their use for treating cancer. The binding agents of the present disclosure comprise one or more antigen binding domains of single domain antibodies which are capable of binding to Cluster of Differentiation 36 (CD36), to Programmed Cell Death protein 1 (PD-1) and / or to Cluster of Differentiation 47 (CD47). The binding agents of the present disclosure are monospecific or multispecific and may be in the form of monomers or multimers.

The present invention discloses a method for preparing a eukaryotic expression vector of Nile tilapia CD36 protein and its application. The method comprises extracting RNA from Nile tilapia intestinal tissue and synthesizing cDNA; performing PCR amplification on the coding sequence fragment of the Nile tilapia CD36 gene to obtain the Nile tilapia CD36 protein gene; and then constructing a eukaryotic expression vector pEGFP-N1-CD36 of the Nile tilapia CD36 protein. The eukaryotic expression vector of the nucleotide sequence of the Nile tilapia CD36 protein prepared by the present invention can be used to prepare a product that improves the anti-streptococcal immunity of tilapia. The preparation of the product is simple, easy to operate, and low in cost. The present invention enhances the anti-streptococcal ability of tilapia by overexpressing the Nile tilapia CD36 protein in tilapia, thereby increasing the survival rate of tilapia infected with Streptococcus agalactiae by 60%. In addition, overexpressing the Nile tilapia CD36 protein in tilapia can also reduce the Streptococcus agalactiae load in tilapia. Therefore, it can be seen that the technical solution of the present invention can effectively induce cellular immunity in tilapia.

To provide a method for identifying a cancer subject for treatment with a Psap peptide.SOLUTION: A subject is identified based on a level of CD36. Further provided herein are a composition and a method for treating a cancer subject based on the level of CD36.SELECTED DRAWING: Figure 2

The purpose of the present invention is to provide a prophylactic, therapeutic or ameliorating drug or food for non-alcoholic steatohepatitis-derived hepatocarcinoma. The present invention pertains to a CD36 inhibitor comprising taxifolin or a salt thereof. The present invention also pertains to a prophylactic, therapeutic or ameliorating drug or food composition for non-alcoholic steatohepatitis-derived hepatocarcinoma.

This invention belongs to the field of biomedical materials technology and discloses a photocontrolled liquefaction hydrogel that inhibits wound scar formation, its preparation method, and its application. The photocontrolled liquefaction hydrogel is composed of the following raw materials: 6-18 parts PVA hydrogel, 3-9 parts borax-boric acid buffer solution, and 1-3 parts PDA@CeO2-SAB nanoparticle suspension. The hydrogel of this invention has the characteristics of photocontrolled liquefaction, precise drug release, inhibition of CD36 expression, good biocompatibility, and biodegradability. It can be used for infected wounds, providing a new, simple, and effective material for inhibiting wound inflammation and promoting scar repair.

The invention discloses an application of a composition of a CD36 inhibitor and a PDK4 inhibitor in preparation of a medicine for treating HFpEF, and the CD36 inhibitor and the PDK4 inhibitor are combined for use and are used for cooperatively regulating and controlling myocardial metabolism reprogramming so as to treat the HFpEF. Through combined application of the CD36 inhibitor and the PDK4 inhibitor, the effects of the combined scheme on a plurality of key indexes such as improvement of the heart diastolic function of an HFpEF mouse, improvement of exercise tolerance, reversal of cardiac hypertrophy, reduction of pulmonary congestion and myocardial fibrosis and the like are remarkably superior to those of any single-drug treatment group of SSO or DCA, and synergistic treatment is achieved.

This invention relates to a compound extracted from *Dryopteris macrocarpa*, its extraction method, and its application in the preparation of drugs for the prevention and / or treatment of non-alcoholic fatty liver disease. This invention provides a novel natural compound obtained from *Dryopteris macrocarpa* for the first time, along with a method for its preparation. Activity studies were conducted, and experimental data show that the compound exhibits low cytotoxicity to normal cells. It can inhibit fatty acid uptake in cells by suppressing the expression of fatty acid uptake-related genes FATP2 and CD36, thereby inhibiting lipid droplet accumulation and reducing cellular lipid levels. This compound can be applied in the preparation of drugs for the prevention and / or treatment of non-alcoholic fatty liver disease.

Certain intestinal or commensal bacteria (produced naturally or in vitro) induce Th17 cells, leading to production of IL-17, reducing lipid absorption, and thereby counteracting metabolic syndrome, obesity, and associated morbidities, such as type-2 diabetes, cardiovascular disease, and NASH / NAFLD. Administration of those bacteria, or of Th17 cells induced by those bacteria, to a subject helps counteract metabolic syndrome and associated morbidities. Antagonists of intestinal CD36 or molecules decreasing intestinal CD36, e.g., IL-17, may also be used to reduce lipid absorption. Depletion of Faecalibacterium rodentium or members of the Erysipelotrichaceae family in the subject may provide a similar result. ILC3 or IL-22 blockade (alone or combined with Th17 cell administration or induction if not already present in the subject), may further provide a similar result, protecting against metabolic disease.

The invention discloses a near-infrared light response fatty acid copper nano-drug as well as a preparation method and application thereof. According to the near-infrared light response fatty acid copper nano-drug, copper nanoparticles serve as a core, the outer layer of the copper nanoparticles is wrapped with a phase-change material organic shell layer, meanwhile, a copper ion carrier is loaded in the organic shell layer, and mitochondrial targeting lipid is modified on the shell layer. The nano-drug constructed by the invention can target tumor cells with high expression of CD36 and increase the dosage in the cells, has good mitochondrial targeting and space-time controllable release characteristics, shows a good photo-thermal treatment effect, can kill the tumor cells more accurately and controllably, and establishes a new strategy for cancer treatment.

The claimed invention relates to treating cancer by targeting CD36, a fatty acid receptor. The claimed invention also relates to treating cancer metastases by targeting CD36. The invention involves using anti-CD36 antibodies as blockers or inhibitors of CD36 activity.